Vitronectin (VTN-N) Recombinant Human Protein, Truncated
Invitrogen17万+抗体限时买二赠一,靶点广,灵活用!
IMPORTANT UPDATE: Vitronectin (VTN-N) Recombinant Human Protein, Truncated, now available under new catalog numbers, A400457 and A400458. Catalog numbers A14700 and A31804 will be discontinued.
Vitronectin (VTN-N) Recombinant Human Protein, Truncated
Gibco™

Vitronectin (VTN-N) Recombinant Human Protein, Truncated

Vitronectin (VTN-N) is a recombinant human protein that provides a defined surface for feeder-free culture of human pluripotent stem cells (PSCs).
Have Questions?
更改视图buttonViewtableView
货号数量
A3180410 mL = 5 mg
A147001 mL = 0.5 mg
货号 A31804
价格(CNY)
8,749.90
飞享价
Ends: 31-Dec-2025
10,438.00
共减 1,688.10 (16%)
Each
添加至购物车
数量:
10 mL = 5 mg
价格(CNY)
8,749.90
飞享价
Ends: 31-Dec-2025
10,438.00
共减 1,688.10 (16%)
Each
添加至购物车

Vitronectin (VTN-N) is a recombinant human protein that provides a defined surface for feeder-free culture of human pluripotent stem cells (PSCs). When used with Essential 8 Medium (Cat. No. A1517001), VTN-N has been proven to maintain pluripotency and normal growth characteristics in multiple PSC lines.

  • Proven to maintain pluripotency and normal growth characteristics in multiple PSC lines when used with Essential 8 Medium
  • Supports PSC growth for >50 passages without any signs of karyotypic abnormalities and to maintain the ability of PSCs to differentiate into all three germ line lineages
  • Supports human pluripotent stem cell attachment and survival better than wild-type vitronectin when used in conjunction with Essential 8 Medium
  • Optimized—designed in the laboratory of James Thomson for use with Essential 8 Medium
  • Defined—for reduced variability in your PSC cultures
  • Supports human pluripotent stem cell attachment and survival better than wild type vitronectin
  • Optimal environment for feeder-free pluripotent stem cell culture
  • Defined, recombinant human protein that reduces variability in your PSC cultures compared to human-plasma derived vitronectin and standard basement membrane extracts (BMEs)
For Research Use Only. Not for use in diagnostic procedures.
规格
最大浓度500 μg/mL
表达系统E. coli
蛋白质形式Recombinant
蛋白质子类型Vitronectin
纯度或质量等级Cell Culture Grade, Endotoxin-Screened
数量10 mL = 5 mg
研究类别Stem Cell Research
运输条件Dry Ice
容积(公制)10 mL
适用于(应用)Stem Cell Culture
形式Liquid
重组Recombinant
种属Human
Unit SizeEach
内容与储存
Store at -80°C and protect from light.

常见问题解答 (FAQ)

之前冻存于其他培养条件的多能干细胞(PSCs)能复苏并后续培养于Gibco Essential 8培养基+玻连蛋白(VTN-N)的组合条件中么?

可以。在mTeSR培养基+BD Matrigel基底膜基质条件下培养并冻存的PSCs细胞可复苏至Gibco Essential 8培养基中并种植于VTN-N基质上。某些细胞系复苏至冻存前的生长培养基及基质中可能会效果更好。在随后的下一次传代过程中,就可使用EDTA将这些细胞传代至Gibco Essential 8培养基+VTN-N的组合中了。

在使用Gibco Essential 8培养基和玻连蛋白(VTN-N)的组合开展细胞培养时,我能否使用分散酶和胶原酶等酶类进行传代?

分散酶与胶原酶一类的酶并不适用于Gibco Essential 8培养基和Gibco玻连蛋白(VTN-N)的组合。使用这些酶类传代会导致细胞活力和贴壁能力下降。

Gibco Essential 8培养基和Gibco玻连蛋白(VTN-N)的组合中推荐用怎样的方法进行细胞传代?

培养在Gibco Essential 8培养基与VTN-N组合中的细胞应使用EDTA进行传代。

在Gibco Essential 8培养基 和Gibco玻连蛋白(VTN-N)的体系中培养的细胞外观如何?

您预期可看到正常的多能干细胞(PSC)形态。PSC的预期生长形态是如图所示的典型形态为,包括边界清晰的紧密聚集克隆和高核质比。

之前培养于其他培养基和基质的多能干细胞(PSC)能换用Gibco Essential 8培养基和Gibco玻连蛋白进行培养么?

培养于其它无饲养层培养体系的细胞,例如mTeSR培养基搭配Matrigel基底膜基质,或StemPro hESC SFM搭配Geltrex基质,也能够成功培养于Gibco Essential 8培养基搭配VTN-N的体系中。此外,在饲养层细胞搭配KnockOut SR中培养的PSC经证明也能够培养于Gibco Essential 8培养基搭配VTN-N的组合中。不过在更换培养基体系之前,细胞必须手工传代或用EDTA进行传代到Gibco Essential 8培养基搭配VTN-N的体系中。

引用和文献 (1)

引用和文献
Abstract
A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids.
Authors:Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zhao Z, Jaffré F, Zhang T, Kim TW, Harschnitz O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen DT, Cioffi M, Chandar V, Hoagland DA, Huang Y, Xiang J, Wang H, Lyden D, Borczuk A, Chen HJ, Studer L, Pan FC, Ho DD, tenOever BR, Evans T, Schwartz RE, Chen S
Journal:Cell Stem Cell
PubMed ID:32579880
SARS-CoV-2 has caused the COVID-19 pandemic. There is an urgent need for physiological models to study SARS-CoV-2 infection using human disease-relevant cells. COVID-19 pathophysiology includes respiratory failure but involves other organ systems including gut, liver, heart, and pancreas. We present an experimental platform comprised of cell and organoid derivatives from ... More